Anti-Coagulants - Qatar

Qatar

The Anti-Coagulants market in Qatar is projected to reach a revenue of US$13.65m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 7.95%, resulting in a market volume of US$20.01m by 2029.
When compared globally, United States will generate the most revenue, amounting to US$16,740.00m in 2024.
Qatar's demand for anti-coagulants is rising due to the growing elderly population and a higher prevalence of chronic diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Coagulants in Qatar has been on a rise in recent years.

Customer preferences: Qatari customers have shown a preference for newer and more advanced Anti-Coagulants that have fewer side effects and are more effective in treating blood clotting disorders. This trend is in line with the global market, where there is a shift towards novel oral anticoagulants (NOACs) as compared to traditional Vitamin K antagonists.

Trends in the market: The Anti-Coagulants market in Qatar is expected to grow at a steady rate due to an increase in the prevalence of cardiovascular diseases, obesity, and diabetes in the country. There has been a rise in the number of patients requiring anticoagulant therapy, which has led to an increase in the demand for these drugs. Additionally, there has been a surge in the number of patients undergoing surgeries and other medical procedures, which has further increased the demand for Anti-Coagulants.

Local special circumstances: Qatar has a high prevalence of cardiovascular diseases, which is a major factor driving the growth of the Anti-Coagulants market in the country. The government has taken several initiatives to improve the healthcare infrastructure in the country, which has led to an increase in the number of hospitals and clinics. This has further increased the demand for Anti-Coagulants in the country.

Underlying macroeconomic factors: The Qatari economy has been growing at a steady rate, which has led to an increase in the disposable income of the population. This has led to an increase in the demand for better healthcare services and drugs. Additionally, the government has been investing heavily in the healthcare sector, which has led to an increase in the availability of healthcare services and drugs in the country. These factors have contributed to the growth of the Anti-Coagulants market in Qatar.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.